Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
Gleason Score & ISUP Grade Group
Distinguishing Grade Group 1 (Gleason 3+3) which requires active surveillance from Grade Group 2 (3+4) or Grade Group 3 (4+3).
Decipher Prostate Genomic Classifier
Quantifies 5-year metastasis risk; can re-stratify intermediate-risk patients to low risk, avoiding hormone therapy.
PSMA (Gallium-68 or F-18) PET-CT
Unrivaled sensitivity for detecting micro-metastatic nodal or bone disease before definitive local surgery or radiation.
BRCA1, BRCA2, ATM & DNA Repair Genes
Dictates eligibility for PARP inhibitors (Olaparib, Talazoparib) and platinum chemotherapy in metastatic castration-resistant disease.
Free PSA & PSA Velocity / Density
Refines risk assessment in men with borderline elevated total PSA (4-10 ng/mL).
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
Active Surveillance vs Active Intervention
Preventing urinary incontinence and erectile dysfunction in men with truly low-risk, organ-confined disease.
Robotic Prostatectomy vs SBRT / Proton Therapy
Balanced comparison of oncologic control, urinary recovery, and bowel toxicity profiles based on baseline anatomy.
Androgen Deprivation Therapy (ADT) Duration
Short-term (4-6 months) vs long-term (24-36 months) ADT alongside radiation for unfavorable intermediate and high-risk disease.
Doublet vs Triplet Systemic Therapy for mHSPC
ADT + ARPI (Enzalutamide/Apalutamide) with or without Docetaxel chemotherapy based on high vs low volume criteria (CHAARTED).
Records Required for Prostate Cancer Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Prostate Cancer
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Pathology Second Opinion
Pathology is the foundational blueprint of every cancer diagnosis, yet it is inherently interpretive. Major peer-reviewed medical studies document that 15% to 30% of second-look pathology reviews uncover diagnostic discordance: benign conditions mistaken for malignant tumors, incorrect tumor staging, missed lymphovascular invasion, or discordant hormone receptor/HER2 status that profoundly alters systemic treatment.
Cancer Radiology Second Opinion
Radiology reports are often produced under high-volume general hospital conditions where subtle oncologic nuances can be overlooked. Up to 20% of expert radiology second opinions identify critical discrepancies: unrecognized liver or peritoneal metastases, missed vascular encasement that alters surgical resectability, or confusion between treatment-induced pseudo-progression and true tumor growth.
Colorectal Cancer Second Opinion
Colorectal cancer treatment branches drastically depending on tumor sidedness, microsatellite instability (MSI/dMMR), extended RAS/BRAF mutations, and HER2 amplification. In rectal cancer, Total Neoadjuvant Therapy (TNT) and watch-and-wait non-operative management can preserve sphincter function. In metastatic disease, aggressive multidisciplinary resection of colorectal liver metastases can achieve long-term cure in up to 35% of patients.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Prostate Cancer Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.